Dr. Hui Zhang is a Professor of Pathology, Oncology, Chemical and Biomolecular Engineering, and Urology, the Director of Mass Spectrometry Core Facility and Proteomic Research, and the Director for Center for Biomarker Discovery and Translation at Johns Hopkins University.

Dr. Hui Zhang graduated from Peking University with a BS and a MS degree and from University of Pennsylvania with a Ph.D. degree. She then worked at New England Biolabs and Cell Signaling Technology, where developed novel antibodies that are broadly reactive to protein post-translational modifications (PTMs) such as phosphorylation, acetylation, sulfation, etc.. She further invented method for proteomic characterization of protein modifications using the broadly reactive PTM-antibodies and mass spectrometry.

She is the inventor for the PTM-antibody development (Production of motif-specific and context-independent antibodies using peptide libraries as antigens. US Patent 7,259,022) and the immunoaffinity isolation of modified peptides from complex mixture using the PTM-antibodies (Immunoaffinity isolation of modified peptides from complex mixtures. US Patent 7,198,896). After moving to the Institute for Systems Biology in 2001, she pioneered the glycoproteomic technology and applied the glycoproteomic technology to the characterization of cell surface proteins and transmembrane proteins for the discovery of cell surface glycoprotein for therapeutic targeting as well as proteins from body fluids for the discovery of proteins that are either shed or secreted from cancer cells. She is the inventor on glycoproteomic characterization method (Methods for quantitative proteome analysis of glycoproteins. US Patent 7,183,118) and the targeted proteomic technology using affinity capture of native and heavy-isotope labeled peptides and mass spectrometric detection (Affinity capture of peptides by microarray and related methods. US Patent 7,794,947).

She was recruited to Johns Hopkins University in 2006, where she further developed glycoproteomic methods for quantitative site-specific glycosylation characterization and glycan imaging (Mass spectrometry imaging of glycans from tissue sections and improved analyte detection methods. US Patent 11,022,613; Quaternary ammonium containing isobaric tag for quantitative glycan profiling. US Patent 10,254,291; Isobaric aldehyde-reactive tags for and analysis of glycans using same. US Patent 20150241437A1). She applied the methods for proteogenomic characterizations of ovarian cancer, kidney cancer, pancreatic cancer, gastric cancer, endometrial cancer, brain cancer, prostate cancer, etc (Biomarkers for prostate cancer. US Patent 8,603,734).

Her contributions to quantitative proteomics, glycoproteomics, targeted proteomics, and proteogenomics are published in about 300 publications including 3 Nature Biotechnology, Cell, Cancer Cell. Her work has been cited for over 27,000 times.

Dr. Naseruddin Höti, MPhil, PhD, ccNRCC, is a distinguished professional with a wealth of experience and expertise in the fields of clinical laboratory sciences, toxicology, virology and cutting-edge diagnostic assays. He is at the forefront of specialized diagnostic and toxicological assay development and implementation. Prior to his current role, Dr. Hoti completed a prestigious ComACC accredited Clinical Chemistry Fellowship at the University of Maryland Medical center. During this fellowship, He honed his skills in clinical laboratory operations, quality control, laboratory management, and analytical methodologies. His contributions included the development, validation, and implementation of innovative laboratory test methods.

Beyond his professional commitments, Dr. Höti holds an adjunct appointment as an Assistant Professor in the Department of Urology at UT Health Sciences in San Antonio, Texas. His academic contributions in translational research have made an enduring impact. Following his graduation, he embarked on a postdoctoral research fellowship at the Johns Hopkins School of Medicine, working under the guidance of Dr. Ronald Rodriguez. During this tenure, Dr. Höti’s contributions to the field were prolific, with a series of high-impact publications on prostate cancer and CRAd viral vectors design.

As a principal investigator for numerous research grants and a former junior faculty member at Johns Hopkins School of Medicine’s Department of Urology, Dr. Höti exemplifies dedication to advancing the frontiers of diagnostic and laboratory medicine. His commitment to combatting cancer through innovative research and clinical practices underscores his unwavering resolve to make meaningful contributions to healthcare.

Personal Websites:

Naseruddin Höti (MPhil, PhD, ccNRCC) | LinkedIn

‪Naseruddin Hoti – ‪Google Scholar

hoti n – Search Results – PubMed (nih.gov)

Dr. Raghothama Chaerkady is a highly accomplished expert in biochemistry, proteomics and known for his exceptional academic achievements. He earned a Ph.D. degree in Biochemistry in 1999 and later pursued a post-doctoral training program at the prestigious Johns Hopkins University School of Medicine. During his time there, he had the privilege of working in the renowned laboratory of Dr. Akhilesh Pandey, further enhancing his knowledge and skills. One of his most noteworthy achievements was the publication of the ground-breaking paper titled “A Draft Map of the Human Proteome” in Nature in 2014. This seminal work reshaped the landscape of proteomics research especially for biomarker discovery.

Dr. Chaerkady is a distinguished specialist in nanoflow liquid chromatography tandem mass spectrometry-based proteomics assays, coupled with exploratory and targeted quantitative profiling. His prowess extends to performing post-translational modification analysis to decode signaling pathways, targeted and untargeted profiling of biomarkers, and orchestrating immuno-enrichment methods for mass spectrometry assays. Beyond his empirical laboratory capabilities, he possesses a unique knack for assisting bioinformatics teams, aiding in the development of efficient data processing, integration, and visualization pipelines.

His formidable academic portfolio includes over a hundred peer-reviewed research publications, amassing more than 12,000 citations with an impressive h-index of 49. Such scholarly prowess solidifies his standing as a respected and recognized leader in the proteomics field.

Leaving the halls of academia for the fast-paced world of industry, Dr. Chaerkady became an integral part of AstraZeneca in 2015. His tenure in this global pharmaceutical titan has seen him masterfully supervising multiomics application in a myriad of drug discovery and validation projects, honing his team management skills and cultivating productive collaborations across various departments within the organization.

Embodying a harmonious blend of academic expertise and industry experience, Dr. Chaerkady has joined Complete Omics as our esteemed Vice President for proteomics. In this pivotal role, he will spearhead our Research and Development for clinical proteomics assays, while also supervising our proteomics service branch. His guidance and leadership will undoubtedly fortify our preeminent position as a service provider to our extensive clientele, consisting of research institutions and industrial partners alike. We anticipate his significant contributions will further cement our status as leaders in the proteomics sector.

Ming Zhang obtained her Bachelor’s degree and her PhD degree in Department of Molecular Biology and Biochemistry from Nankai University with a research focus on disease-causing gene identification and signaling pathway analysis. She then pursued her Postdoctoral training in the University of Rochester in New York, USA and joined Johns Hopkins University School of Medicine as a Research Associate Faculty and obtained her certificate of genetics and genome analysis. Her research interest is to develop new NGS technologies and to apply them to cancer diagnostics and therapeutics.

Ming is the only Research Faculty focusing on cancer genome under the direction of Dr. Bert Vogelstein. In recent years, she has finished large-scale cancer genome analysis for numerous human cancers, including pancreatic cancer, GI track cancers, brain cancer, and endometrial cancer, etc. By defining the genomic landscapes of these cancers, her work has supported the identification of cancer-associated biomarkers and therapeutic targets including several kinases and metabolic enzymes, which are now prevailing drug targets under investigation of major pharmaceutical companies. A lot of genetic biomarkers have been identified from Ming’s work for early cancer diagnostics and many of them have been approved by WHO and are being used in hospitals globally. In the recent 5 years, Ming and Dr. Vogelstein have published over 30 research papers together on high profile scientific journals, such as The New England Journal of Medicine, Nature Genetics, PNAS, Cancer Discovery, Gastroenterology etc., and her recent findings have been cited for over 7000 times.

In addition to her scientific responsibilities, Ming holds the pivotal role of Chief Intellectual Property Officer at Complete Omics. Accredited by the USPTO as a certified intellectual property agent, she expertly directs the safeguarding and patenting of all intellectual properties developed by the company.

Liang Zhao received his Ph.D. degree of Analytical Chemistry in 2011 from University of the Pacific. He then continued his research in analytical chemistry by pursuing a post-doctoral training in Johns Hopkins University Center for Alternatives to Animal Testing (CAAT) at the Bloomberg School of Public Health.

In 2012, he took the initiative, as a core member, in establishing the CAAT center’s metabolomic core facility and took the leadership for two research projects related to toxicological mechanism studies using a variety of metabolomic technologies. In 2014, he reported a high-throughput metabolic profiling strategy which made characterization of a series of in vitro 3D brain models possible for the prediction of developmental neurotoxicity and neurodegeneration. His work was published on PNAS.

After joining the School of Medicine in Johns Hopkins University as a faculty member in 2017, his research interest has been focusing on tumor- and immuno- metabolomics. As the only faculty member dedicated to metabolomics in the center, he is responsible for project design, training graduate student and lab management. In his research of this period of time, he led his team and developed a stable isotope labeling (carbon/nitrogen tracing) technique to explore the metabolic activities of different cell subsets in tumor micro-environment. With this state-of-the-art approach he has developed, a series of surprising differences in metabolic pathways fueling cancer cells and effector T cells were discovered and a representative work was recently published on SCIENCE in 2019. Now his discoveries are being further exploited as a metabolic checkpoint for a variety of novel cancer therapeutics by numerous research institutions and pharmaceuticals.

He is striving in integrating mass spectrometry, molecular biology and bioinformatics to explore the biomedical importance of metabolites, and to better translate metabolomics findings into clinical applications, such as the development of new biomarker and AI-enhanced diagnostic panels, as well as exploring novel therapeutic approaches for cancers.